This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which are ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group.

Weight loss of 5% or greater was achieved by 79.2% of patients on semaglutide 25mg vs 31.1% of those on placebo (P <.0001). Semaglutide-treated patients also saw significant improvements in ...

These famous faces have opened up about their differing weight loss journeys Leah Puttkammer/FilmMagic; Alexander Tamargo/Getty; Gilbert Flores/Variety via Getty People can seek to lose weight for ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

which studied 25 milligram dose of oral semaglutide compared to placebo in 307 adults with obesity with one or more comorbidities. The company is also studying weight-loss pill amycretin ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

It's a brand name for tirzepatide — also known as Zepbound — which is highly effective for weight loss by reducing appetite and improving how the body breaks down sugar and fat. Weight Loss ...

In a new study, the semaglutide weight loss drug helped 2 out of 3 people with a life-threatening condition linked to fat accumulation in the liver. In a late-stage clinical trial, Wegovy ...

LONDON - The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults ... But it also notes that the active ingredient in one of the newer drugs, ...